Catalog No.: PC-61288Not For Human Use, Lab Use Only.
Tegavivint (BC-2059, Tegatrabetan) is an orally bioavailable β-catenin antagonist that disrupts the binding of β-catenin to transducin β-like 1 (TBL1) and promotes β-catenin degradation, attenuates nuclear and cytoplasmic levels of β-catenin.
Tegavivint (BC-2059, Tegatrabetan) is an orally bioavailable β-catenin antagonist that disrupts the binding of β-catenin to transducin β-like 1 (TBL1) and promotes β-catenin degradation, attenuates nuclear and cytoplasmic levels of β-catenin.
BC-2059 reduces transcriptional activity of TCF4 and expression of its target genes, cyclin D1, c-MYC and survivin.
BC-2059 treatment dose-dependently induced apoptosis of cultured and primary AML BPCs.
BC-2059 significantly improves the median survival of immune-depleted mice engrafted with either cultured or primary AML BPCs.
